In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocycline. A randomized prospective comparative study should be performed to confirm our encouraging results.
Treatment of human brucellosis with rifampin plus minocycline / A. Cascio, F. Scarlata, S. Giordano, S. Antinori, C. Colomba, L. Titone. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 15:3(2003), pp. 248-252.
Treatment of human brucellosis with rifampin plus minocycline
S. AntinoriWriting – Original Draft Preparation
;
2003
Abstract
In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocycline. A randomized prospective comparative study should be performed to confirm our encouraging results.File | Dimensione | Formato | |
---|---|---|---|
Treatment of Human Brucellosis with Rifampin plus Minocycline.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
256.45 kB
Formato
Adobe PDF
|
256.45 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.